Skip to main content
A

ABSCINT

The startup develops in vivo diagnostics using single-domain antibodies for molecular imaging, focusing on immunology, oncology, and cardiology. Their technology enables precise disease diagnosis, treatment selection, and monitoring of treatment response based on specific molecular markers, improving patient outcomes in oncology and cardiovascular care.

Liège, BelgiumFounded 2020111K+ followers
Updated 20 months ago

Funding

$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

QF
Funding rounds are not available yet.

Founders

Product

Features

  • The startup develops in vivo diagnostics using single-domain antibodies for molecular imaging, focusing on immunology, oncology, and cardiology. Their technology enables precise disease diagnosis, treatment selection, and monitoring of treatment response based on specific molecular markers, improving patient outcomes in oncology and cardiovascular care.
This profile is AI-generated and may contain inaccuracies.